TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients

Courtney A. Crane, Seunggu J. Han, Jeffery J. Barry, Brian J. Ahn, Lewis L. Lanier, Andrew T. Parsa

Research output: Contribution to journalArticlepeer-review

189 Scopus citations


The activating receptor NKG2D, expressed by natural killer (NK) cells and CD8+ T cells, has a role in the specific killing of transformed cells. We examined NKG2D expression in patients with glioblastoma multiforme and found that NKG2D was downregulated on NK cells and CD8+ T cells. Expression of NKG2D on lymphocytes significantly increased following tumor resection and correlated with an increased ability to kill NKG2D ligand-positive tumor targets. Despite the presence of soluble NKG2D ligands in the sera of glioblastoma patients, NKG2D downregulation was primarily caused by tumor-derived tumor growth factor-β, suggesting that blocking of this cytokine may have therapeutic benefit.

Original languageEnglish (US)
Pages (from-to)7-13
Number of pages7
Issue number1
StatePublished - Jan 2010
Externally publishedYes


  • GBM
  • Immune escape NKG2D
  • NK cell
  • TGF-β

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'TGF-β downregulates the activating receptor NKG2D on NK cells and CD8<sup>+</sup> T cells in glioma patients'. Together they form a unique fingerprint.

Cite this